UK Approves Regeneron – Roche’s COVID-19 Antibody Cocktail
The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Roche Holding AG (OTC:RHHBY) to…
Roche’s Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage
Genentech and Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization
AstraZeneca, Daiichi Sankyo’s Enhertu Shows Improved PFS Over Roche’s Kadcyla In Breast Cancer
AstraZeneca plc (NASDAQ:AZN) and Daiichi Sankyo Co Ltd (OTC:DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3 trial of Enhertu. The…
Genentech’s Polivy Plus R-CHP Shows Prolonged Survival In Newly Diagnosed DLBCL Patients
Genentech, a member of Roche Holdings AG (OTC:RHHBY), announced that the pivotal Phase 3 POLARIX trial met its primary endpoint in people…
Billionaire Masayoshi Son’s SoftBank Claims $5B Stake In Roche: Bloomberg
SoftBank Group Corp (OTC:SFTBF) has quietly acquired a $5 billion stake in Roche Holdings AG (OTC:RHHBF), making it one of the…
FDA Approves Regeneron – Roche’s COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
Following the June update that allowed for a lower dose of REGEN-COV, the FDA has again expanded emergency use authorization for the…
Roche Puts Alzheimer’s Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters
Roche Holding AG (OTC:RHHBY) is reportedly talking to the FDA about its Alzheimer’s disease drug candidate, gantenerumab. CEO Severin Schwan declined…
Spark Therapeutics’ Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression
Spark Therapeutics, a unit of Roche Holdings AG (OTC:RHHBY), has announced updated data from the ongoing Phase 1/2 trial of SPK-8011 gene…
AbbVie – Roche’s Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes
The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A treatment Hemlibra.